Aileron Therapeutics has reportedly released positive data from its ongoing Phase 1b clinical trial of ALRN-6924, effectively demonstrating that patients with p53-mutated small cell lung cancer (SCLC) experienced protective effect against neutropenia, severe anemia, and thrombocytopenia upon treatment with ALRN-6924 before the second-line administration of topotecan.

According to the President and CEO of Aileron, Manuel Aivado, M.D, PhD, these positive results for ALRN-6924 bring the company a major step closer towards its objective of developing a new paragon of proactive prevention of chemotherapy-induced side effects for addressing a major unmet need amongst cancer patients. Aivado has also stated that the company appreciates that physicians require assurance regarding the non-reduction of chemotherapy’s efficacy by a chemoprotective agent.

Aivado further added that ALRN-6924 delivers this assurance as it has been designed for shielding only healthy and non-p53-mutated cells, leaving p53-mutated cancer cells completely vulnerable to chemotherapy. With the ongoing clinical development of ALRN-6924, the company believes in its potential of bringing chemoprotection to patients across a wide range of cancer types by enhancing their quality of life and improving their anti-cancer response to chemotherapy.

Studies cite that the cornerstone of treatment for millions of cancer patients, chemotherapy, fails to differentiate between healthy cells and cancer cells, destroying both, cancer cells and rapidly dividing healthy cells, comprising skin cells, bone marrow cells, and hair follicle cells, amongst others. ALRN-6924 reportedly represents the first and only chemoprotective therapy under clinical development that utilizes biomarker strategy, state sources.

Aileron, Chief Medical Officer, Vojislav Vukovic, M.D., PhD, stated that the company is thrilled to have achieved proof of concept in its current Phase 1b clinical trial, adding that ALRN-6924 has demonstrated its capability to protect very sick SCLC patients against life-threatening and severe toxicities and side effects associated with chemotherapy.

Vukovic added, Aileron now has the validation to extend clinical development into other categories of chemotherapies and p53-mutated cancers by pursuing its long-term objective of bringing chemoprotection to all p53-mutated cancer patients irrespective of chemotherapy or cancer type.

Source credit: